Parvus Therapeutics Announces a Publication Describing the Cellular Origin of Treg Cells Generated Endogenously by Navacim Therapy

Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. - May 09, 2023

Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201

Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021

Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles

Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021

Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments

Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021

Press Releases 1 - 4 of 4